



**Are you a teen or young adult lymphoma survivor that has finished treatment?**

**If so, you may be eligible to participate in this study that could make a positive impact on the AYA cancer community.**

## Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult (AYA) Cancer Survivors

### **WHY** consider participating in this study?

- Survivors of cancer diagnosed in adolescence or young adulthood (ages 18–39) have a higher risk of multiple health problems, due to having unique experiences that have effects on their overall health, mental health, and quality of life.
- EAQ211 is being done to answer the following questions:
  - How do life circumstances and mental health affect human gene activity and health outcomes for AYA lymphoma survivors?
  - Do differences in life circumstances or mental health contribute to differences in gene activity and health outcomes for some AYAs after completion of lymphoma cancer treatment?
- Furthermore, this study aims to find out how to improve care for AYAs diagnosed with and treated for lymphoma. EAQ211 may inform future research and care by identifying who may be at increased risk for long-term late effects and medical problems associated with cancer treatment.

### **WHAT** does this study involve?

- If you choose to participate in EAQ211, you will fill out an initial survey that asks a variety of questions about your health, environment, and quality of life. You will also provide a blood sample, either collected at your clinic or at an alternate location/time of your choice via mobile phlebotomy.
  - After that, you will complete an online survey and provide a blood sample every 6 months for 24 months (5 surveys and 5 blood draws total). The surveys will each take about 20 minutes to complete.

You agree to take part in the study and sign the consent form

Registration is completed for the study

Complete online questionnaires and provide blood samples 5 times over two years



## WHO will take part in this study?

---

- Approximately 2,000 disease-free survivors of Hodgkin and Non-Hodgkin lymphoma will participate in EAQ211. You must be 18–39 years of age and must have completed treatment in the past 12 months.
- Please note, you can decide to stop participating in the study at any time.

## WHAT are the costs of taking part in this study?

---

- You may receive up to \$100 in gift cards for participating in this study. You will receive a \$20 gift card of your choosing after each time that you complete an online survey and provide a blood sample.
- You and/or your insurance provider will not have to pay for the blood collections or the research tests.
- Depending on your personal cell phone plan, there may be added costs related to receiving text notifications from the study team that will remind you when surveys are available to be completed. Also, there may be added costs to your cellphone bill if you complete the online surveys using a personal smartphone or tablet without Wi-Fi.

## IF you would like to know more

---

- About the EAQ211 study, talk with your doctor, or:
  - Visit [www.ecog-acrin.org](http://www.ecog-acrin.org) and search EAQ211, then select the link to the EAQ211 Home Page.
    - » For information about locations where the study is available, scroll down the page to Locations and Contacts and click the + sign.
  - Visit [www.aftercancerogenomics.org](http://www.aftercancerogenomics.org) or follow @cancerogenomics\_ on social media.
  - Call the NCI Cancer Information Service at 1-800-4-CANCER (1-800-422-6237).
- About clinical trials:
  - General cancer information: visit the NCI website at [www.cancer.gov](http://www.cancer.gov)
  - Insurance coverage: visit [www.cancer.gov/clinicaltrials/learningabout/payingfor](http://www.cancer.gov/clinicaltrials/learningabout/payingfor)
- About ECOG-ACRIN:
  - Visit [www.ecog-acrin.org](http://www.ecog-acrin.org)
  - For a list of patient resources and links to patient advocacy groups, visit <https://ecog-acrin.org/patients/resources>

@cancerogenomics\_

